Vivos Therapeutics, Inc. VVOS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -77.75% | -122.37% | -90.10% | -36.08% | -18.91% |
| Total Depreciation and Amortization | 131.69% | 159.15% | 125.30% | 72.53% | 31.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.88% | 24.09% | -25.25% | -35.23% | 267.44% |
| Change in Net Operating Assets | 440.39% | 217.68% | 235.95% | 153.94% | -301.62% |
| Cash from Operations | -18.82% | -25.09% | -20.27% | -15.14% | -29.74% |
| Capital Expenditure | -50.56% | -315.03% | -312.15% | -71.65% | -135.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 99.03% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 69.74% | -1,276.99% | -1,225.00% | -975.70% | -1,104.72% |
| Total Debt Issued | -57.93% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -28.42% | -25.32% | -62.25% | -60.09% | 146.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.79% | -25.50% | 38.50% | -2.45% | -203.04% |
| Cash from Financing | -10.20% | 73.21% | 3.82% | -6.05% | 25.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.08% | 13.75% | -191.64% | -160.57% | -184.46% |